(Q34252801)

31 July 2017

Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy (English)

1 reference

31 July 2017

0 references

1 reference

1 reference

Kathrine Holte

1

1 reference

PubMed ID

22548675

31 July 2017

Aleksander Krag

series ordinal

2

1 reference

PubMed ID

22548675

31 July 2017

Lise Lotte Gluud

series ordinal

3

1 reference

31 July 2017

30 April 2012

1 reference

31 July 2017

1 reference

31 July 2017

42

1 reference

31 July 2017

10

1 reference

31 July 2017

1008-1015

1 reference

Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

31 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Pathogenetic mechanisms of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Rifaximin treatment in hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Bias in clinical intervention research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Probiotic yogurt for the treatment of minimal hepatic encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

Probiotics for patients with hepatic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2012.01015.X

10.1111/J.1872-034X.2012.01015.X

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

22548675